Cited 0 time in
Overcoming the age-dependent SARS-CoV-2 vaccine response through hybrid immunity: analysis of humoral and cellular immunity with mass cytometry profiling
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Gerelkhuu, Zayakhuu | - |
| dc.contributor.author | Park, Sehee | - |
| dc.contributor.author | Lee, Kyoung Hwa | - |
| dc.contributor.author | Kim, Yong Chan | - |
| dc.contributor.author | Kwon, Sook Jin | - |
| dc.contributor.author | Song, Kyoung-Ho | - |
| dc.contributor.author | Kim, Eu Suk | - |
| dc.contributor.author | Song, Young Goo | - |
| dc.contributor.author | Park, Yoon Soo | - |
| dc.contributor.author | Ahn, Jin Young | - |
| dc.contributor.author | Choi, Jun Yong | - |
| dc.contributor.author | Choi, Won Suk | - |
| dc.contributor.author | Bae, Seongman | - |
| dc.contributor.author | Kim, Sung-Han | - |
| dc.contributor.author | Kim, Shin-Woo | - |
| dc.contributor.author | Kwon, Ki Tae | - |
| dc.contributor.author | Jeong, Hye Won | - |
| dc.contributor.author | Peck, Kyong Ran | - |
| dc.contributor.author | Kang, Eun-Suk | - |
| dc.contributor.author | Koh, June-Young | - |
| dc.contributor.author | Ko, Jae-Hoon | - |
| dc.contributor.author | Yoon, Tae Hyun | - |
| dc.date.accessioned | 2024-11-28T08:27:39Z | - |
| dc.date.available | 2024-11-28T08:27:39Z | - |
| dc.date.issued | 2024-07 | - |
| dc.identifier.issn | 1742-4933 | - |
| dc.identifier.issn | 1742-4933 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/195097 | - |
| dc.description.abstract | Background: Age-dependent immune responses to coronavirus disease 2019 (COVID-19) vaccinations and breakthrough infections (BIs) in young and middle-aged individuals are unclear. Methods: This nationwide multicenter prospective cohort study analyzed immune responses in participants of the ChAdOx1 (ChAd)-ChAd-mRNA vaccine group using cytometry by time-of-flight, anti-spike protein antibody (Sab) and anti-nucleocapsid antibody (Nab) titers, plaque reduction neutralization tests (PRNTs), and interferon-gamma (IFN-γ) release assays at various time points. Results: We evaluated 347 participants with an average age of 38.9 ± 9.4 years (range: 21–63). There was a significant inverse correlation between age and Sab levels after the second dose (slope − 14.96, P = 0.032), and this was more pronounced after the third dose (slope − 208.9, P < 0.001). After BIs, older participants showed significantly higher Sab titers (slope 398.8, P = 0.001), reversing the age-related decline observed post-vaccination. This reversal was also observed in PRNTs against wild-type SARS-CoV-2 and the BA.1 and BA.5 variants. IFN-γ responses increased markedly after the third dose and Bis, but showed a weak positive correlation with age, without statistical significance. Immune cell profiling revealed an age-dependent decrease in the proportions of B-cell lineage cells. The proportions of naive CD4+ and CD8+ T cells were inversely correlated with age, whereas the proportions of mature T cell subsets with memory function, including memory CD4+ T, CD8+ TEM, CD8+ TEMRA, and TFH cells, increased with age. Conclusions: Age-dependent waning of the serologic response to COVID-19 vaccines occurred even in middle-aged individuals, but was reversed after BIs. IFN-γ responses were preserved, compensating for the decrease in naive T cell populations, with an increase in memory T cell populations. | - |
| dc.format.extent | 11 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | BioMed Central | - |
| dc.title | Overcoming the age-dependent SARS-CoV-2 vaccine response through hybrid immunity: analysis of humoral and cellular immunity with mass cytometry profiling | - |
| dc.type | Article | - |
| dc.publisher.location | 영국 | - |
| dc.identifier.doi | 10.1186/s12979-024-00454-z | - |
| dc.identifier.scopusid | 2-s2.0-85200033650 | - |
| dc.identifier.wosid | 001281060900001 | - |
| dc.identifier.bibliographicCitation | Immunity and Ageing, v.21, no.1, pp 1 - 11 | - |
| dc.citation.title | Immunity and Ageing | - |
| dc.citation.volume | 21 | - |
| dc.citation.number | 1 | - |
| dc.citation.startPage | 1 | - |
| dc.citation.endPage | 11 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Geriatrics & Gerontology | - |
| dc.relation.journalResearchArea | Immunology | - |
| dc.relation.journalWebOfScienceCategory | Geriatrics & Gerontology | - |
| dc.relation.journalWebOfScienceCategory | Immunology | - |
| dc.subject.keywordPlus | adult | - |
| dc.subject.keywordPlus | age | - |
| dc.subject.keywordPlus | aging | - |
| dc.subject.keywordPlus | antibody titer | - |
| dc.subject.keywordPlus | Article | - |
| dc.subject.keywordPlus | B lymphocyte | - |
| dc.subject.keywordPlus | breakthrough infection | - |
| dc.subject.keywordPlus | CD4+ T lymphocyte | - |
| dc.subject.keywordPlus | CD8+ T lymphocyte | - |
| dc.subject.keywordPlus | cell lineage | - |
| dc.subject.keywordPlus | cellular immunity | - |
| dc.subject.keywordPlus | cohort analysis | - |
| dc.subject.keywordPlus | controlled clinical trial | - |
| dc.subject.keywordPlus | controlled study | - |
| dc.subject.keywordPlus | coronavirus disease 2019 | - |
| dc.subject.keywordPlus | correlation analysis | - |
| dc.subject.keywordPlus | cytokine response | - |
| dc.subject.keywordPlus | drug dose | - |
| dc.subject.keywordPlus | drug response | - |
| dc.subject.keywordPlus | female | - |
| dc.subject.keywordPlus | human | - |
| dc.subject.keywordPlus | human cell | - |
| dc.subject.keywordPlus | human experiment | - |
| dc.subject.keywordPlus | humoral immunity | - |
| dc.subject.keywordPlus | immune response | - |
| dc.subject.keywordPlus | immunocompetent cell | - |
| dc.subject.keywordPlus | interferon gamma release assay | - |
| dc.subject.keywordPlus | longitudinal study | - |
| dc.subject.keywordPlus | male | - |
| dc.subject.keywordPlus | mass cytometry | - |
| dc.subject.keywordPlus | memory T lymphocyte | - |
| dc.subject.keywordPlus | multicenter study | - |
| dc.subject.keywordPlus | normal human | - |
| dc.subject.keywordPlus | plaque reduction neutralization test | - |
| dc.subject.keywordPlus | prospective study | - |
| dc.subject.keywordPlus | SARS-CoV-2 (lineage BA.1) | - |
| dc.subject.keywordPlus | SARS-CoV-2 (lineage BA.5) | - |
| dc.subject.keywordPlus | serology | - |
| dc.subject.keywordPlus | Severe acute respiratory syndrome coronavirus 2 | - |
| dc.subject.keywordPlus | T lymphocyte subpopulation | - |
| dc.subject.keywordPlus | Tfh cell | - |
| dc.subject.keywordPlus | time of flight mass spectrometry | - |
| dc.subject.keywordPlus | vaccination | - |
| dc.subject.keywordPlus | virus strain | - |
| dc.subject.keywordPlus | wild type | - |
| dc.subject.keywordAuthor | Aging | - |
| dc.subject.keywordAuthor | COVID-19 vaccines | - |
| dc.subject.keywordAuthor | Immunity | - |
| dc.subject.keywordAuthor | Mass cytometry | - |
| dc.identifier.url | https://immunityageing.biomedcentral.com/articles/10.1186/s12979-024-00454-z | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
